natgillin/translations-raw huggingface dataset:
Excipients: Tris hydrochloride, sodium chloride, mannitol (E421), pentetic acid, polysorbate 80, sodium hydroxide, hydrochloric acid, water for injections.
Pomožne snovi: tris v obliki klorida, natrijev klorid, manitol (E421), pentetska kislina, polisorbat 80, natrijev hidroksid, klorovodikova kislina in voda za injekcije.
Excipients: trometamol, anhydrous citric acid, cysteine hydrochloride monohydrate and water for injections.
Pomožne snovi: trometamol, brezvodna citronska kislina, cistein klorid monohidrat in voda za injekcije.
Excipients: trometamol, ethanol 96%, sodium chloride, hydrochloric acid (for pH adjustment), water for injections.
Pomožne snovi: trometamol, etanol 96 %, natrijev klorid, klorovodikova kislina (za uravnavanje vrednosti pH), voda za injekcije.
Excipients: zinc chloride, metacresol, glycerol, hydrochloric acid (for pH adjustment), polysorbate 20, sodium hydroxide (for pH adjustment), water for injections
Pomožne snovi: cinkov klorid, metakrezol, glicerol, klorovodikova kislina (za uravnavanje pH), polisorbat 20, natrijev hidroksid (za uravnavanje pH), voda za injekcije.
Excipients: zinc chloride, metacresol, glycerol, hydrochloric acid (for PH adjustment), sodium hydroxide (for PH adjustment), water for injections
Pomožne snovi: cinkov klorid, meta-krezol, glicerol, klorovodikova kislina (za uravnavanje pH), natrijev hidroksid (za uravnavanje pH), voda za injekcije.
Excipients: zinc chloride, metacresol, glycerol, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injections
Pomožne snovi: cinkov klorid, metakrezol, glicerol, klorovodikova kislina (za uravnavanje pH), natrijev hidroksid (za uravnavanje pH), voda za injekcije.
Excipients: zinc chloride, metacresol, glycerol, hydrochloric acid (for pH adlustment), sodium hydroxide (for pH adlustment), water for injections
Pomožne snovi: cinkov klorid, metakrezol, glicerol, klorovodikova kislina (za uravnavanje pH), natrijev hidroksid (za uravnavanje pH), voda za injekcije.
Excipients: zinc chloride, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections
Pomožne snovi: cinkov klorid, meta-krezol, glicerol, klorovodikova kislina in natrijev hidroksid (za uravnavanje pH) in voda za injekcije.
Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections
Pomožne snovi: cinkov oksid, metakrezol, glicerol, klorovodikova kislina in natrijev hidroksid (za prilagajanje pH), voda za injekcije
Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections
Pomožne snovi: cinkov oksid, metakrezol, glicerol, klorovodikova kislina in natrijev hidroksid (za prilagoditev pH), voda za injekcije.
Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections
Pomožne snovi: cinkov oksid, metakrezol, glicerol, klorovodikova kislina in natrijev hidroksid (za uravnavanje pH), voda za injekcije
Excipients: -(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)-- methoxypoly(oxyethylen)-40 sodium salt, fully hydrogenated soy phosphatidylcholine, cholesterol, ammonium sulphate, sucrose, histidine, water for injections, hydrochloric acid and sodium hydroxide.
Pomožne snovi: α-(2-[1,2-distearoil-sn-glicero(3)fosfooksi]etilkarbamoil)-ω-metoksipoli(oksietilen)- 40 natrijeva sol, popolnoma hidrogeniran sojin fosfatidilholin, holesterol, amonijev sulfat, saharoza, histidin, voda za injekcije, klorovodikova kislina, natrijev hidroksid.
Excipientwith known effect:
Pomožna snov z znanim učinkom:
Excipientwith known effect: each film-coated tablet contains 73.80 mg lactose (asmonohydrate).
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 73,80 mg laktoze (v obliki monohidrata).
Excipientwith known effect:each film coated tablet contains 183.13 mg lactose (asmonohydrate).
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 183,13 mg laktoze (v obliki monohidrata).
Excipientwith known effect:each film-coated tablet contains 183.13 mg lactose (asmonohydrate)
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 183,13 mg laktoze (v obliki monohidrata).
Excipientwith known effect:each film-coated tablet contains 221.39 mg lactose (as monohydrate)
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 221,39 mg laktoze (v obliki monohidrata).
Excipientwith known effect:each film-coated tablet contains 295.18 mg lactose (asmonohydrate).
Pomožna snov z znanim učinkom: ena filmsko obložena tableta vsebuje 295,18 mg laktoze (v obliki monohidrata).
Excludes those of the vertebrae, skull, facial, mandible, metacarpus, and finger and toe phalanges.
Izključuje zlome vretenc, lobanje, obraza, spodnje čeljusti, metakarpalne zlome in zlome prstnic na rokah in nogah.
Excluding non-melanoma of the skin, 121 malignancies including 5 cases of lymphoma were observed in the Cimzia RA clinical trials in which a total of 4,049 patients were treated, representing 9,277 patient- years.
Če ne upštevamo nemelanomskega raka kože, so v okviru kliničnih raziskav za zdravilo Cimzia za revmatoidni artritis, v katerem je sodelovalo 4.049 bolnikov, opazili 121 malignih obolenj, vključno s 5 primeri limfoma, kar predstavlja 9,277 bolnikovih let.
Exclusion criteria encompassed patients at high risk of bleeding (see sections 4.3 and 4.4), patients who were not expected to survive for 28 days due to a pre-existing, non-sepsis related medical condition, HIV positive patients whose most recent CD4 count was  50/mm3, patients on chronic dialysis, and patients who had undergone bone marrow, lung, liver, pancreas or small bowel transplantation, and patients with acute clinical pancreatitis without a proven source of infection.
Merila za izključitev so obsegala bolnike z velikim tveganjem za krvavitev (glejte poglavji 4.3 in 4.4), bolnike, za katere niso pričakovali, da bodo preživeli 28 dni zaradi predhodnih zdravstvenih stanj, ki niso bila povezana s sepso, HIV pozitivne bolnike, katerih zadnja koncentracija CD4 je bila  50/mm3, bolnike zdravljene s kronično dializo, bolnike, ki so imeli presajen kostni mozeg, pljuča, jetra, trebušno slinavko ali tanko črevo, in bolnike z akutnim klinično zaznavnim pankreatitisom brez dokazanega vira okužbe.
Exclusion criteria included visceral (liver, lung, or brain) metastases, malignant pleural effusions or malignant ascites, pathologic long bone fractures, imminent pathologic long-bone fractures (cortical erosion on radiography >50%), spinal cord compression, moderate to severe prostate cancer-related pain and use of narcotics for cancer- related pain, and treatment with chemotherapy at least 3 months prior to randomisation.
Izključitveni kriteriji so vključevali visceralne (jetra, pljuča ali možgani) metastaze, maligni plevralni izliv ali maligni ascites, patološke zlome dolgih kosti, grozeče patološke zlome dolgih kosti (erozija korteksa na radiografiji > 50 %), kompresija hrbtenjače, zmerna do huda z rakom povezana bolečina in uporaba narkotikov zaradi bolečin, povezanih z rakom in zdravljenje s kemoterapijo v roku prejšnjih
Exclusion Criteria: limited to contraindications outlined in section 4.3 of the SmPC
Nevključitveni kriteriji: omejeni na kontraindikacije, navedene po poglavju 4.3 Povzetka glavnih značilnosti zdravila.
Exclusion of pregnancy prior to treatment initiation and monthly pregnancy testing during treatment.
Izključitev nosečnosti pred začetkom zdravljenja in mesečno izvajanje testov nosečnosti med zdravljenjem.
Excoriation, genital injury, limb injury, skeletal injury, soft tissue injury, spinal fracture, thoracic vertebral fracture, tooth fracture
ekskoriacija, genitalna poškodba, poškodbe udov, poškodbe kosti, poškodbe mehkih tkiv, zlom hrbtenice, zlom prsnega vretenca, zlom zoba
Excretion data from the 14C study indicated that at least about 82 to 95 % of the dose is absorbed.
Podatki o ekskreciji iz študije 14C so pokazali, da se absorbira vsaj 82 do 95% odmerka.
Excretion is primarily via faeces (61%), with renal elimination of unchanged active substance and metabolites accounting for 16% of the administered dose.
Izloča se predvsem z blatom (61 %); skozi ledvice se v obliki nespremenjene zdravilne učinkovine in presnovkov izloči 16 % uporabljenega odmerka.
Excretion of unchanged bosutinib in urine was low with approximately 1% of the dose in both healthy subjects and those with advanced malignant solid tumours.
Izločanje nespremenjenega bosutiniba v urin je bilo majhno tako pri zdravih preiskovancih kot pri tistih z napredovanimi malignimi solidnimi tumorji, in sicer približno 1 % odmerka.
Excretion: After oral administration of 14C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days.
Izločanje: Po peroralni uporabi s C-označenim razagilinom nastopi izločanje v glavnem preko urina (62,6 %) in sekundarno preko blata (21,8 %), s celotnim izločanjem 84,4 % odmerka v 38 dnevih.
Exelon
Cog Exelon
Exelon 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “EXELON 1,5 mg” on the body.
Exelon 1,5 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rumen pokrovček in rumeno telo kapsule z rdečim napisom “EXELON 1,5 mg”.
Exelon 13.3 mg/24 h transdermal patches: Each patch releasing 13.3 mg of rivastigmine per 24 hours is 15 cm2 and contains 27 mg of rivastigmine.
Exelon 13,3 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 13,3 mg rivastigmina na 24 ur, je velik 15 cm2 in vsebuje 27 mg rivastigmina.
Exelon 3.0 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “EXELON 3 mg” on the body.
Exelon 3,0 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo oranžen pokrovček in oranžno telo kapsule z rdečim napisom “EXELON 3 mg”.
Exelon 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “EXELON 4,5 mg” on the body.
Exelon 4,5 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rdeč pokrovček in rdeče telo kapsule z belim napisom “EXELON 4,5 mg”.
Exelon 4.6 mg/24 h transdermal patches: Each patch releasing 4.6 mg of rivastigmine per 24 hours is 5 cm2 and contains 9 mg of rivastigmine.
Exelon 4,6 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 4,6 mg rivastigmina na 24 ur, je velik 5 cm2 in vsebuje 9 mg rivastigmina.
Exelon 6.0 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “EXELON 6 mg” on the body.
Exelon 6,0 mg trde kapsule, ki vsebujejo belkast do rahlo rumen prašek, imajo rdeč pokrovček in oranžno telo kapsule z rdečim napisom “EXELON 6 mg”.
Exelon 9.5 mg/24 h transdermal patches: Each patch releasing 9.5 mg of rivastigmine per 24 hours is 10 cm2 and contains 18 mg of rivastigmine.
Exelon 9,5 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 9,5 mg rivastigmina na 24 ur, je velik 10 cm2 in vsebuje 18 mg rivastigmina.
Exelon capsules have also been studied in 541 patients with dementia due to Parkinson’s disease.
Kapsule zdravila Exelon so proučevali tudi pri 541 bolnikih z demenco kot posledico Parkinsonove bolezni.
Exelon has been studied in mild to moderately severe Alzheimer’s disease.
Zdravilo Exelon so proučevali pri blagi do zmerno hudi Alzheimerjevi bolezni.
Exelon is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Zdravilo Exelon uporabljamo za zdravljenje odraslih bolnikov z blago do zmerno hudo Alzheimerjevo demenco, to je napredujoča bolezen možganov, ki postopoma prizadene spomin in intelektualne sposobnosti ter vpliva na vedenje bolnika.
Exelon is used for the treatment of patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Zdravilo Exelon se uporablja za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, tj. napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
Exelon might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).
Zdravilo Exelon bi lahko vplivalo na zdravljenje z antiholinergičnimi zdravili (zdravili, ki se uporabljajo za lajšanje želodčnih krčev ali spazmov, za zdravljenje Parkinsonove bolezni ali za preprečevanje slabosti na potovanju).
Exelon might interfere with anticholinergic medicines some of which are medicines used to relieve stomach cramps or spasms (e.g. dicyclomine), to treat Parkinson’s disease (e.g. amantadine) or to prevent motion sickness (e.g. diphenhydramine, scopolamine, or meclizine).
Zdravilo Exelon lahko vpliva na antiholinergična zdravila, med katera sodijo zdravila. ki se uporabljajo za lajšanje želodčnih krčev (npr. diciklomin), za zdravljenje Parkinsonove bolezni (npr. amantadin) ali za preprečevanje potovalne slabosti (npr. difenhidramin, skopolamin ali meklizin) oziroma ta zdravila lahko vplivajo na rivastigmin.
Exelon must also not be used in patients who are suspected to have had in the past a severe allergic reaction called ‘allergic contact dermatitis’ to Exelon patch.
Prva tako ga ne smejo uporabljati bolniki, pri katerih obstaja sum, da so v preteklosti doživeli hudo alergijsko reakcijo, imenovano „alergijski kontaktni dermatitis“, na obliže zdravila Exelon.
Exelon oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug.
Peroralna raztopina Exelon je na voljo v obliki 50 ml ali 120 ml bistre rumene raztopine (2,0 mg/ml baze), v jantarno obarvani steklenici z za otroke varno zaporko, oblogo iz penaste gume, s kapalnim vložkom in s prilegajočim se zamaškom.
Exelon Patch should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting).
Zdravila Exelon obliži ne smete jemati sočasno z metoklopramidom (zdravilom, ki ga uporabljamo za ublažitev ali preprečevanje navzee (slabosti s siljenjem na bruhanje) in bruhanja).
Exelon rivastigmine
Exelon rivastigmin
Exelon should not be used during pregnancy unless clearly necessary.
Zdravila Exelon v času nosečnosti ne smete uporabljati, če to ni nujno potrebno.
Exelon transdermal patches
Exelon transdermalni obliži
Exenatide is cleared primarily by the kidney; therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide.
Eksenatid se izloča zlasti preko ledvic, zato ni pričakovati, da bi okvara jeter vplivala na koncentracije eksenatida v krvi.
Exercise caution when administering eltrombopag to patients with hepatic disease.
Pri bolnikih z boleznijo jeter je treba eltrombopag uporabljati s previdnostjo.
exercise less than usual
te telesno manj dejavni kot običajno,
Exercise Like muscles, bones need exercise to stay strong and healthy.
Telesna aktivnost Tako kot za mišice je tudi za kosti potrebna telesna aktivnost, da ostanejo močne in zdrave.
exercise more than usual
te telesno bolj dejavni kot običajno,
exercised when boceprevir
boceprevirja s
exertional,
Zelo pogosti
exfoliative and
eksfoliativnim in
Exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
Poročali so o pojavu exsfoliatnih kožnih reakcijah, kot npr. sindrom Steven-Johnson in toksična epidermalna nekroliza.
Exfoliative dermatitis
eksfoliativni dermatitis
Exfoliative dermatitis, erythematous rash, pruritus
eksfoliativni dermatitis, kožni izpuščaji, pruritus
Exfoliative rash
eksfoliativni izpuščaj
Exfoliative rash (G3/4: 0.3%)
eksfoliacijski izpuščaj (S 3/4: 0,3 %)
Exfoliative rash*
eksfoliativni izpuščaj
Exfoliative rash, skin exfoliation, necrolytic migratory erythema, blood blister, dermatitis allergic, skin reaction, dermatitis acneiform, erythema, increased tendency to bruise, purpura, hyperhidrosis, night sweats, nail atrophy, pigmentation disorder, skin discoloration, hypertrichosis
eksfoliativni izpuščaj, luščenje kože, nekrolitični migratorni eritem, krvavi mehur, alergijski dermatitis, kožna reakcija, akneiformni dermatitis, eritem, hitrejši pojav modric, purpura, hiperhidroza, nočno potenje, atrofija nohtov, motnje pigmentacije, obarvanje kože, hipertrihoza,
Exfoliative skin conditions including Stevens-Johnson syndrome Erythema multiforme
Eksfoliativne bolezni kože, vključno s Stevens-Johnsonovim sindromom Multiformni eritem
exfoliative skin conditions including Stevens-Johnson syndrome*,†
eksfoliativna stanja na koži, vključno s Stevens-Johnsonovim sindromom*,
Exfoliative skin disorders in general, including Stevens-Johnson Syndrome (SJS), are already listed in section 4.8 of the SmPCs of Incresync, Vipdomet and Vipidia.
Eksfoliativne bolezni kože, vključno s Stevens-Johnsonovim sindromom, so na splošno že navedene v poglavju 4.8 povzetkov glavnih značilnosti zdravil Incresync, Vipdomet in Vipidia.
Exforge 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side.
Tablete zdravila Exforge 5 mg/80 mg so okrogle in temnorumene; na eni strani imajo oznako “NVR” in na drugi “NV”.
Exforge and older people (age 65 years or over)
Zdravilo Exforge in starejši ljudje (stari 65 let ali več)
Exforge can be used with or without food.
Bolnik lahko zdravilo Exforge vzame s hrano ali brez nje.
Exforge has not been studied in any patient population other than hypertension.
Zdravilo Exforge ni raziskano pri nobeni drugi populaciji, razen pri bolnikih s hipertenzijo.
Exforge is contraindicated in patients with severe hepatic impairment (see section 4.3).
Pri bolnikih s hudo okvaro jeter je zdravilo Exforge kontraindicirano (glejte poglavje 4.3).
Exforge must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives’ class, to valsartan, or to any of the other ingredients.
Zdravila Exforge ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) amlodipin ali druga zdravila iz razreda derivatov dihidropiridina, valsartan ali katero koli drugo sestavino zdravila.
EXIST-1 (CRAD001M2301): This was a randomised, double-blind, controlled, phase III trial of everolimus (n=78) versus placebo (n=39) in patients with TSC who have SEGA, irrespective of age.
EXIST-1 (CRAD001M2301): To je bilo randomizirano, dvojno slepo, kontrolirano preskušanje everolimusa (n=78) faze III v primerjavi s placebom (n=39) pri bolnikih s TSC, ki imajo SEGA, ne glede na starost.
EXIST-2 (CRAD001M2302): This was a randomised, double-blind, controlled, phase III trial of everolimus (n=79) versus placebo (n=39) in patients with either TSC plus renal angiomyolipoma (n=113) or sporadic lymphangioleiomyomatosis (LAM) plus renal angiomyolipoma (n=5).
EXIST-2 (CRAD001M2302): To je bilo randomizirano, dvojno slepo, kontrolirano preskušanje everolimusa (n=79) faze III v primerjavi s placebom (n=39) pri bolnikih, ki so imeli bodisi TSC in ledvični angiomiolipom (n=113) bodisi sporadično limfangioleiomiomatozo (LAM) in ledvični angiomiolipom (n=5).
Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicidal attempt.
Obstoječa huda psihiatrična bolezen ali huda psihiatrična bolezen v anamnezi, še posebej huda depresija, samomorilne misli ali poskus samomora.
Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt.
Obstoječa huda duševna bolezen ali huda duševna bolezen v anamnezi, še posebej huda depresija, samomorilne misli ali poskus samomora.
Existing data suggest that evening dosing might have some advantages in the mean IOP reduction.
Obstoječi podatki kažejo, da ima odmerjanje zvečer lahko nekatere prednosti pri zmanjševanju srednje vrednosti očesnega tlaka.
Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions.
Ličinke se lahko, glede na klimatske razmere, pojavljajo 6 ali več tednov pa začetnem nanosu.
Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions.
Ponovna infestacija z novimi bolhami iz okolice lahko traja, glede na klimatske razmere, šest tednov ali dlje po začetnem nanosu.
EXJADE 125 mg dispersible tablets EXJADE 250 mg dispersible tablets EXJADE 500 mg dispersible tablets Deferasirox
EXJADE 125 mg disperzibilne tablete EXJADE 250 mg disperzibilne tablete EXJADE 500 mg disperzibilne tablete deferasiroks
EXJADE 125 mg tablets are stamped “J 125” on one side and “NVR” on the other.
Tablete zdravila EXJADE 125 mg imajo na eni strani vtisnjeno oznako “J 125”, na drugi pa “NVR“.
EXJADE 180 mg film-coated tablets are medium blue and stamped “180” on one side and “NVR” on the other.
Filmsko obložene tablete zdravila EXJADE 180 mg so srednje modre in imajo na eni strani vtisnjeno oznako “180”, na drugi pa “NVR“.
EXJADE 250 mg tablets are stamped “J 250” on one side and “NVR” on the other.
Tablete zdravila EXJADE 250 mg imajo na eni strani vtisnjeno oznako “J 250”, na drugi pa “NVR“.
EXJADE 360 mg film-coated tablets are dark blue and stamped “360” on one side and “NVR” on the other.
Filmsko obložene tablete zdravila EXJADE 360 mg so temno modre in imajo na eni strani vtisnjeno oznako “360”, na drugi pa “NVR“.
EXJADE 500 mg tablets are stamped “J 500” on one side and “NVR” on the other.
Tablete zdravila EXJADE 500 mg imajo na eni strani vtisnjeno oznako “J 500”, na drugi pa “NVR“.
EXJADE 90 mg film-coated tablets are light blue and stamped “90” on one side and “NVR” on the other.
Filmsko obložene tablete zdravila EXJADE 90 mg so svetlo modre in imajo na eni strani vtisnjeno oznako “90”, na drugi pa “NVR“.
EXJADE contains lactose
Zdravilo EXJADE vsebuje laktozo
EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation (see section 5.2).
Zdravilo EXJADE filmsko obložene tablete imajo večjo biološko razpoložljivost v primerjavi z zdravilom EXJADE disperzibilne tablete (glejte poglavje 5.2).
EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation.
Zdravilo EXJADE filmsko obložene tablete imajo večjo biološko razpoložljivost v primerjavi z zdravilom EXJADE disperzibilne tablete.
EXJADE has minor influence on the ability to drive and use machines.
Zdravilo EXJADE ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Exjade is a medicine that contains the active substance deferasirox.
Exjade je zdravilo, ki vsebuje zdravilno učinkovino deferasiroks.
EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
Zdravilo EXJADE je indicirano tudi za zdravljenje kronične preobremenitve z železom zaradi transfuzij krvi v primerih, ko je zdravljenje z deferoksaminom kontraindicirano ali neprimerno pri naslednjih skupinah bolnikov:
EXJADE is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.
Zdravilo EXJADE poleg tega uporabljamo tudi, kadar je zdravljenje z deferasiroksom kontraindicirano ali neprimerno pri bolnikih, ki so stari 10 let ali več in imajo preobremenitev z železom in sindrome talasemije, vendar ti niso posledica transfuzij.
Exjade is not recommended for patients with severe liver problems as it has not been tested in these patients.
Zdravilo Exjade ni priporočeno za uporabo pri bolnikih s hudimi težavami z jetri, saj v tej skupini ni bilo preskušeno.